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Aim: The aims of the Danish Registry of Childhood and Adolescent Diabetes (DanDiabKids) 
are to monitor and improve the quality of care for children and adolescents with diabetes in 
Denmark and to follow the incidence and prevalence of diabetes.
Study population: The study population consists of all children diagnosed with diabetes 
before the age of 15 years since 1996. Since 2015, every child followed up at a pediatric center 
(,18 years of age) will be included.
Main variables: The variables in the registry are the quality indicators, demographic variables, 
associated conditions, diabetes classification, family history of diabetes, growth parameters, 
self-care, and treatment variables. The quality indicators are selected based on international 
consensus of measures of good clinical practice. The indicators are metabolic control as assessed 
by HbA1c, blood pressure, albuminuria, retinopathy, neuropathy, number of severe hypoglycemic 
events, and hospitalization with ketoacidosis.
Descriptive data: The number of children diagnosed with diabetes is increasing with ∼3% 
per year mainly for type 1 diabetes (ie, 296 new patients ,15 years of age were diagnosed in 
2014). The disease management has changed dramatically with more children treated intensively 
with multiple daily injections, insulin pumps, and increased number of self-monitored blood 
glucose values per day. These initiatives have resulted in a significant improvement in HbA1c 
over the years and a decrease in the number of children experiencing severe hypoglycemia, 
diabetic nephropathy, and retinopathy.
Conclusion: The systematic collection of data in DanDiabKids documents improved quality 
of care over the last 12 years, despite a substantial increase in the number of patients cared for 
by pediatric departments in Denmark, fulfilling the purpose of the registry.
Keywords: DanDiabkids, treatment modalities, HbA1c, severe hypoglycemia, quality of care
Aim of the registry
The aims of the registry are to improve and monitor the quality of care for children 
and adolescents with diabetes in Denmark and to follow the incidence and prevalence 
of diabetes over time. Furthermore, the registry supports and encourages research in 
the area of childhood diabetes.
Study population
The study population consists of all children diagnosed with diabetes before the age 
of 15 years since 1996, including all children followed up by a pediatric department 
since 1996.1 Since 2015, every child aged up to 18 years admitted to a pediatric 
 center will be included, thereby extending the study population in the future. In 2014, 
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328 new patients were included, of whom 296 were ,15 years 
of age. Over the years 1996–2014, a total of 5,602 children 
have been included (Figure 1). In the beginning, only children 
with type 1 diabetes (T1D) based on a clinical diagnosis were 
included, and after 2006, children with all types of diabetes 
were included. There is a continuous merging with the  Danish 
National Patient Register with all International Statistical 
Classification of Diseases and Related Health Problems-tenth 
revision (ICD10) codes for diabetes (ie, DE10.x, DE11.x, 
DE12.x, DE13.x, DE14.x). Once a year, all patients in the 
National Patient Register not found in the Danish Registry 
of Childhood and Adolescent Diabetes (DanDiabKids) are 
validated to ensure that all children with diabetes are regis-
tered in DanDiabKids.
Main variables
The demographic variables include the municipality at onset, 
ethnicity, sex, and age at onset of diabetes. The  completeness 
of data is 100%, except for ethnicity, where ,1% were 
 missing in 2014.
The classification is primarily based on a clinical pre-
sentation, but it is possible to register genetics, stimulated 
C-peptide, and autoantibody titers if measured. Family 
 history of diabetes is recorded only at onset.
The main variables for monitoring and improving  quality of 
care in the registry are the quality indicators.2,3 The indicators 
are selected based on international consensus of measures 
of good clinical practice. All indicators are defined based on 
international standards.2,4 The outcome indicators are meta-
bolic control expressed as glycated hemoglobin (HbA1c), 
blood pressure (BP), albuminuria, retinopathy, neuropathy, 
number of severe hypoglycemic events, and hospitalization 
with ketoacidosis (Figure 2). Once a year, .90% of the par-
ticipating centers send one HbA1c sample to Copenhagen 
University  Hospital at Herlev. The Department of Pediatrics 
at Copenhagen University Hospital has its own specialized 
laboratory where the determination of HbA1c is performed 
for all participating centers in Denmark according to the 
International Federation of Clinical Chemistry, whereas one-
third of locally measured HbA1c are determined with a non-
standardized immunoturbidimetric assay (the DCA Vantage® 
Analyzer [DCA 2000 HbA1c system, Bayer AG, Leverkusen, 
Germany]). BP was first selected as an outcome indicator in 
2013; this variable has not yet been validated. Guidelines 
for measuring BP follow international standards. The data 
completeness for BP was 87% in 2014 and is anticipated 
to increase in the coming years, where a national clinical 
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Figure 1 Newly diagnosed patients per year.
Notes: The number of patients diagnosed per year categorized according to the 
latest classification. MODY is based on genetic tests. Some individuals were initially 
diagnosed as type 1 diabetes but later reclassified due to new genetic tests. The 
ascertainment is .99% per year.
Abbreviations: MODY, maturity onset diabetes of the young; DM, diabetes mellitus.
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Figure 2 HbA1c and severe hypoglycemic events (per 100 person-years).
Notes: The fluctuation in HbA1c (bars) and the incidence of severe hypoglycemic 
events (unconsciousness or seizures [circles]) during the last 12 years in children 
diagnosed with type 1 diabetes before the age of 15 years. HbA1c is in mmol/mol 
(bars), whereas the incidence of hypoglycemia (iR) is number per 100 person-years 
(circles). Data completeness increased from 1996 to 2000 and then stabilized above 
75%; since 2006, data completeness has exceeded 80%.
Abbreviations: IR, incidence rates per 100 person-years; HbA1c, glycated hemoglobin.
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guideline of at least 95% being screened will be implemented. 
Presently, a definition of hypertension is not included because 
we have not had access to calculation of a percentile/standard 
deviation (SD) score. This is now available, and an indicator 
defining the acceptable number of children with hyperten-
sion, who have not started pharmacological treatment, will 
be defined. For most variables, data completeness is .75% 
since 2000 and ,20% is missing from 2006 onward.
The number of severe hypoglycemic events (loss of 
consciousness/seizures) is recorded at each visit in the 
outpatient clinic and summarized to the annual status for 
each individual. The episodes have to be confirmed with 
a measured blood glucose ,3.5 mmol/L or consciousness 
being reestablished after glucagon or IV glucose infusion, 
to exclude epilepsy or other medical reasons for seizure. If 
the number of hypoglycemic events exceeds ten per year, the 
pediatric center is contacted to confirm whether the number 
is correct. The number of hospitalizations with ketoacidosis 
is recorded similarly and summarized once yearly. The bicar-
bonate or pH at admission has to be registered in order to 
include only those with confirmed ketoacidosis – defined as 
standard bicarbonate ,15 mmol/L or pH ,7.3. There were 
∼5% missing registrations of hypoglycemia and 7% missing 
registrations of ketoacidosis in 2014. These numbers have 
been stable in the last 3–5 years.
Screening and monitoring for microvascular complica-
tions (retinopathy, nephropathy, neuropathy) are initiated 
at 12 years, 15 years, and 18 years of age. Before 2010, 
screening for microalbuminuria was based on timed over-
night urinary albumin excretion rate (.20 µg/min). Due to 
insufficient data completeness, the screening procedure was 
changed to a spot urine (albumin/creatinine ratio). If negative, 
this is sufficient, but if positive (.2.5 mg/mmol in males and 
.3.5 mg/mmol in females), two additional overnight mea-
sures of albumin excretion are required. At least two positive 
measures of albumin excretion within a period of 6 months 
are necessary to confirm microalbuminuria. The change in 
the procedure has led to increased data completeness. There 
was a screening completeness of 93% in 2014. Screening 
for retinopathy is accepted either as eye fundus examination 
(fundoscopy) or by two-field 40°–60° fundus photography. 
Most of the retinopathies are screened by fundus photography. 
Screening completeness shows huge variation across regions, 
with 80% at the national level, indicating potentials for 
improvement. Missing screening is sometimes due to the fact 
that some of the patients are screened by an ophthalmologist 
or in an eye-care center outside the hospital, and information 
regarding the examinations is not returned to the primary 
clinic. Neuropathy is screened using biothesiometry. There 
is no clear international definition of neuropathy in children, 
and the challenge is that the threshold values for vibration 
sense increase with linear height. So far, we have used adult 
limits for neuropathy of 20 V, which is too coarse and leads 
to none of the children being diagnosed with neuropathy. The 
plan is to define limits for children below and above 150 cm 
of height based on measures in healthy children.
Growth is measured annually by linear height, body 
weight, and body mass index. Outliers, defined as values of 
3SD from the mean, are validated by sending patient lists to 
the departments for confirmation. Furthermore, it is impos-
sible to register a height lower than previous measures in 
the registry.
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Figure 3 Treatment modalities and glucose monitoring.
Notes: (A) The number of children treated with different insulin types or insulin 
pumps per year. Data completeness increased from 1996 to 2000 and thereafter 
stabilized above 75%; since 2006, it has been stable above 80%. (B) The number of 
SMBG per day registered for children with diabetes per year or the number using 
CGMS .1 week per month. Using CGMS .1 week per month overrules the 
number of SMBG. Data completeness increased from 1996 to 2000 and thereafter 
stabilized above 75%; since 2006, is has been stable above 80%.
Abbreviations: CGMS, continuous glucose monitoring; SMBG, self-monitored 
blood glucose values; NPH, neutral protamine hagedorn.
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The treatment and self-care are recorded annually, 
including injection methods, insulin types, number of injec-
tions or boluses, and self-monitoring of glucose (Figure 3). 
There are 5%–10% missing data on these variables during 
the recent years.
T1D is associated with other autoimmune manifestations, 
especially celiac and thyroid disease. It is recommended 
that celiac disease is screened annually for the first 3 years 
after diagnosis and thereafter in case of symptoms. Celiac 
disease and thyroid disease are not mandatory variables in 
the  registry, but all centers are recommended to follow inter-
national guidelines regarding screening for thyroid diseases, 
which means screening at onset and every second year there-
after, if no obvious signs of thyroid disease are present.
The standard of each quality indicator and registration 
practice of variables is discussed at annual meetings, where 
results comparing different centers are discussed. Each year, 
a subset of variables is in focus. Currently, a clear, practical, 
and clinical-oriented definition and screening procedure for 
microvascular complications and hypertension are in focus.
Follow-up
The registry was initiated in 1996, and since then, there has 
been an annual screening and monitoring for microvascular 
complications. The registry is run by the steering committee 
for the Danish Study Group of Childhood Diabetes. From 
2006 to 2011, each center twice a year received a list with 
lacking variables for the indicators, allowing for each center 
to be aware of missing variables. Unfortunately, since the 
work with the annual report has been centralized, the centers 
have not had access to lists of missing values influencing 
data completeness. These lists have now been published in 
January 2016.
Examples of research
Based on the register data, the incidence of T1D in children 
is found to increase with .3% a year,5 whereas the increase 
of type 2 diabetes in the young people is nonexisting in 
Denmark.6 We have demonstrated that metabolic control has 
improved7 and severe hypoglycemic events have decreased.8,9 
Furthermore, diabetic ketoacidosis at disease onset is associ-
ated with worse metabolic control and higher daily insulin 
requirement for equal HbA1c values (ie, higher insulin dose-
adjusted [IDA]A1c)10 several years after diagnosis.11
The treatment with insulin pumps and the influence of 
pump treatment on glycemic control have also been evalu-
ated. We found a significantly better HbA1c in pump users 
compared to children on multiple daily insulin  injections 
but a parallel increase in HbA1c with longer diabetes 
duration.12,13
In collaboration with the Swedish, Norwegian, and 
 Icelandic registries, we have investigated the influence of 
ethnicity on metabolic control and found a slightly higher 
HbA1c in those of nonnative ethnicity, though the differ-
ence differed between countries and was less than that seen 
previously.14
The prevalence of celiac disease in healthy children and 
children with T1D in Denmark and Sweden has been inves-
tigated by the presence of autoantibodies.15 More Swedish 
children with T1D were positive compared to the Danish 
children. However, the surprising finding was a relatively high 
prevalence of celiac antibodies in 2.8% of healthy Danish 
population compared to 0.3% of the Swedish population.
Administrative issues and funding
The registry was developed in 1995 by Professors Knut 
Borch-Johnsen and Henrik B Mortensen in collaboration with 
the diabetologists working at pediatric departments treating 
children with diabetes. The development of the register was 
initially funded by Danish Pharmaceutical Association and 
Novo Nordisk A/S. Later, the yearly costs were covered by 
the  Copenhagen County. At present, the steering committee 
has access to funding of ∼€10,000 annually to cover expenses 
for validation, comments of annual reports, and data export. 
Since 2011, DanDiabKids has been collaborating with the 
Adult Diabetes Registry and Diabetic Eye Registry together 
in the Danish Diabetes Database. Before 2012, DanDiabKids 
independently prepared the annual reports, and statistical and 
epidemiologic expertise were funded by “The Danish Study 
Group on Childhood Diabetes”.1 Since 2012, this work has 
been centralized under the Danish Diabetes Database.
Conclusion
Despite a higher workload treating the increasing number of 
children with diabetes in Denmark, the pediatric departments 
in Denmark have managed to improve patient outcome, 
that is, lowering of HbA1c and a decrease in episodes with 
severe hypoglycemia. This is likely to lead to a substantial 
reduction in morbidity and mortality for young adults with 
diagnoses of diabetes in childhood. The quality-focused 
registry has fulfilled the purpose of monitoring and  following 
the prevalence and incidence of the disease and has led to 
improved quality of care in children and adolescents with 
diabetes in Denmark.
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